Free Trial
NYSE:STE

STERIS Q1 2026 Earnings Report

STERIS logo
$232.67 -0.65 (-0.28%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$231.61 -1.06 (-0.46%)
As of 07:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STERIS EPS Results

Actual EPS
N/A
Consensus EPS
$2.32
Beat/Miss
N/A
One Year Ago EPS
N/A

STERIS Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.36 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

STERIS Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

STERIS Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
STERIS plc (STE)
See More STERIS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like STERIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on STERIS and other key companies, straight to your email.

About STERIS

STERIS (NYSE:STE) is a global provider of infection prevention, contamination control and surgical support equipment and services headquartered in Dublin, Ireland, with major operations in Mentor, Ohio. The company develops and delivers a wide range of products and solutions designed to support the healthcare, pharmaceutical, medical device and research industries in maintaining clean and safe environments. Its core offerings include sterilization equipment, surgical instrumentation, single-use sterile products and comprehensive service and validation programs.

In its healthcare segment, STERIS supplies hospitals, ambulatory surgery centers and physician offices with steam and low-temperature sterilizers, endoscope reprocessing systems, surgical tables, lights and equipment management solutions. The life sciences and pharmaceutical segment addresses critical contamination control needs for drug and device manufacturers through cleanroom solutions, washer-disinfectors, isolators, safety-engineered stoppers, sealing systems and contract sterilization services for oxygen and hydrogen peroxide cycles.

Founded in 1985 as STERIS Corporation and later restructured as an Ireland-domiciled public limited company following the 2019 merger with UK-based Synergy Health, the firm has grown its footprint through strategic acquisitions and organic investment in research and development. Past acquisitions include Key Surgical, Integrated Medical Systems Corporation and Cantel Medical’s sterilization business. James P. Lawrence, appointed President and Chief Executive Officer in 2014, leads an executive team focused on innovation, regulatory compliance and global expansion.

STERIS operates in more than 25 countries with manufacturing facilities, service centers and distribution networks spanning North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. The company’s service organization delivers on-site maintenance, validation, asset management and training, while its global regulatory and quality teams support customers in meeting stringent regional and international standards.

View STERIS Profile

More Earnings Resources from MarketBeat